Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REGENERON PHARMACEUTICALS

(REGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Regeneron says COVID-19 drug could be less effective against Omicron variant

11/30/2021 | 06:15am EST

Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc said on Tuesday prior analyses suggested its COVID-19 antibody drug could have reduced activity against the Omicron coronavirus variant. (Reporting by Manas Mishra in Bengaluru; Editing by Shounak Dasgupta)


ę Reuters 2021
All news about REGENERON PHARMACEUTICALS
01/13WHO recommends Eli Lilly, GSK-Vir's drugs, widening COVID-19 treatment pool
RE
01/13Regeneron to Report Fourth Quarter and Full Year 2021 Financial and Operating Results a..
PR
01/12EUROPEAN MIDDAY BRIEFING - Stocks Higher as -3-
DJ
01/12EUROPEAN MIDDAY BRIEFING - Stocks Higher as -2-
DJ
01/11ADRs Close Higher; Nokia Trades Actively
DJ
01/10Regeneron and ultragenyx collaborate to commercialize evkeeza (evinacumab) outside the ..
AQ
01/10Regeneron's Covid-19 Antibody Cocktail Had 2021 U.S. Sales Near $6 Billion
DJ
01/10REGENERON PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Regulatio..
AQ
01/07Regeneron Pharmaceuticals, Ultragenyx Pharmaceutical Strike Commercialization Deal for ..
MT
01/07Regeneron, Ultragenyx Ink International Deal on Cholesterol Drug Evkeeza
DJ
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS
More recommendations
Financials (USD)
Sales 2021 15 484 M - -
Net income 2021 7 967 M - -
Net cash 2021 4 033 M - -
P/E ratio 2021 8,74x
Yield 2021 -
Capitalization 64 327 M 64 327 M -
EV / Sales 2021 3,89x
EV / Sales 2022 4,31x
Nbr of Employees 9 766
Free-Float -
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 615,24 $
Average target price 699,18 $
Spread / Average Target 13,6%
EPS Revisions
Managers and Directors
Leonard S. Schleifer Co-President, Chief Executive Officer & Director
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl Executive VP-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
REGENERON PHARMACEUTICALS-2.58%64 327
GILEAD SCIENCES, INC.-1.16%90 027
VERTEX PHARMACEUTICALS6.58%59 510
WUXI APPTEC CO., LTD.-3.73%52 722
BIONTECH SE-23.97%47 338
BEIGENE, LTD.-11.92%24 519